FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
🤖AI Özeti
Johnson & Johnson has received approval from the U.S. Food and Drug Administration for its new once-daily pill designed to treat psoriasis. This medication is notable as it is the first oral treatment that competes with existing injectable therapies like Tremfya and Skyrizi. The approval marks a significant advancement in the treatment options available for psoriasis patients, who often prefer oral medications over injections.
💡AI Analizi
📚Bağlam ve Tarihsel Perspektif
Psoriasis is a chronic skin condition that affects millions of people worldwide, often leading to significant discomfort and reduced quality of life. The introduction of oral treatments provides an alternative for patients who are hesitant to use injections, which can be more invasive and less convenient.
This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for medical guidance.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.